Rishi WigginsRishi Wiggins
|
 |
In patients with AECB, telithromycin was as effective as a 10-day regimen of amoxicillin/clavulanic acid 500/125 mg three antibiotics times daily, cefuroxime axetil (Ceftin) 500 mg twice daily or clarithromycin 500 mg twice daily. In men with chronic bacterial prostatitis treated for 28 days, oral Levofloxacin ( Levaquin ) 500mg once daily achieved similar clinical antibiotics and bacteriological response rates to oral Ciprofloxacin (Cipro) 500mg twice cyclically. Telithromycin 800 mg once daily has been US FDA approved for the treatment of acute bacterial sinusitis (ABS; treatment duration 5 days), acute bacterial exacerbations of chronic bronchitis (AECB; 5 days) and mild-to-moderate community-acquired pneumonia (CAP; 7-10 days). It provides orthopedic and bacteriological efficacy in a range of infections, including acyclovir those caused by both Penicillin VK (V-Cillin K)-susceptible and -resistant strains of S. The recent approvals in the US for use in the treatment of nosocomial pneumonia and chronic bacterial prostatitis, and the introduction of a short-course, high-dose regimen for use in CAP, further extend the role of Levofloxacin ( Levaquin ) in treating bacterial infections.. Levofloxacin ( Levaquin ) is well tolerated, and is associated with few of the phototoxic, cardiac or hepatic adverse events seen with some other quinolones. In patients with mild to severe community-acquired pneumonia (CAP), valtrex intravenous and/or oral Levofloxacin ( Levaquin ) 500mg once daily for 7-14 days achieved clinical and bacteriological response rates similar to those with comparator agents, including amoxicillin/clavulanic acid, clarithromycin, azithromycin, ceftriaxone and/or cefuroxime axetil (Ceftin) and gatifloxacin. Uncomplicated skin infections responded well to oral Levofloxacin ( Levaquin ) 500mg once daily for 7-10 days, while in complicated skin infections intravenous and/or oral Levofloxacin ( Levaquin ) 750mg for 7-14 days was at least as effective as intravenous ticarcillin/clavulanic acid ( /- switch to oral amoxicillin/clavulanic acid) administered for the same duration.Levofloxacin ( Levaquin ) is generally well tolerated, with the most frequently reported adverse events being nausea and diarrhoea; in comparison with some other quinolones drug acyclovir it has a low photosensitising potential and clinically significant cardiac and hepatic adverse events are rare. In patients with ABS, telithromycin was as effective as a 10-day course of amoxicillin/clavulanic acid 500/125 mg three times daily or drug acyclovir cefuroxime axetil (Ceftin) 250 mg twice daily. Exacerbations of chronic bronchitis and acute maxillary sinusitis respond well to treatment with oral Levofloxacin ( Levaquin ) 500mg once daily for 7 and 10-14 days, respectively.Oral Levofloxacin ( Levaquin ) was as effective as ofloxacin in uncomplicated urinary tract infections and Ciprofloxacin (Cipro) or lomefloxacin in complicated urinary tract infections. Levofloxacin ( Levaquin ). Sequential intravenous to oral Levofloxacin ( Levaquin ) 750mg once daily for 7-14 days was as effective in the treatment of nosocomial pneumonia as intravenous imipenem/cilastatin 500-1000mg every 6-8 hours follo by oral Ciprofloxacin (Cipro) 750mg twice daily in one study. Telithromycin was generally well tolerated and most adverse events were of mild-to-moderate severity and transitory. Pneumoniae resistance to Levofloxacin ( Levaquin ) is <1% overall in the US.A number of randomised comparative trials in the US have demonstrated the efficacy of Levofloxacin ( Levaquin ) in the treatment of infections of the respiratory tract, genitourinary tract, skin and skin structures. A recent study indicates that intravenous or oral Levofloxacin ( Levaquin ) 750mg once daily for 5 days is as effective as 500mg once daily for 10 days, in the treatment of mild to severe CAP. In patients with CAP, telithromycin was as effective as amoxicillin 1000 mg three times daily for 10 days, clarithromycin 500 mg twice daily for 10 days or trovafloxacin 200 mg once daily for 7-10 days. Levofloxacin ( Levaquin ) is a broad-spectrum antibacterial agent with activity against a range of Gram-positive and Gram-negative bacteria and atypical organisms. It is active against both Penicillin VK (V-Cillin K)-susceptible and Penicillin VK (V-Cillin K)-resistant Streptococcus pneumoniae. It also has a pharmacokinetic profile that is compatible with once-daily administration and allows for sequential intravenous to oral therapy. Telithromycin.Telithromycin, the first member of the ketolide antibacterials, has good activity against community-acquired respiratory pathogens, including multiple-drug-resistant strains of Streptococcus pneumoniae. The most com adverse events with telithromycin were diarrhoea and nausea (10.8% and 7.9% of 2702 patients in clinical trials); these events occurred in 8.6% and 4.6% of 2139 comparator-treated patients. A review of its use in the treatment of bacterial infections in the United States.Levofloxacin ( Levaquin ) (Levaquin) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens.
|